The acquisition of AstraZeneca Plc (AZ) would achieve Pfizer Inc. (NYSE:PFE)’s strategic aims as the deal promises significant benefits for the combined entity, according to Fitch Ratings. The transaction would amass scale for Pfizer, broaden the company’s portfolio and pipeline and could provide some tax advantages.Pfizer Inc. (NYSE:PFE) shares after opening at $32.06 moved to $32.09 on last trade day and at the end of the day closed at $31.76. Company price to sales ratio in past twelve months was calculated as 3.94 and price to cash ratio as 6.27. Pfizer Inc. (NYSE:PFE) showed a positive weekly performance of 2.45%.
Bristol-Myers Squibb Co (NYSE:BMY) updated its FY14 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $1.70-1.80 for the period, compared to the Thomson Reuters consensus estimate of $1.77. The company issued revenue guidance of $15.2-15.8 billion, compared to the consensus revenue estimate of $15.53 billion. Bristol-Myers Squibb Co (NYSE:BMY) shares fell -2.07% in last trading session and ended the day on $49.32. BMY return on equity ratio is recorded as 17.70% and its return on assets is 6.90%. Bristol-Myers Squibb Co (NYSE:BMY) yearly performance is 27.21%.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has started second phase trial of AP26113 in patients with locally advanced lung cancer who were earlier treated with crizotinib. This trial is designed to ascertain efficacy and safety of AP26113 in patients who test positive for ALK+ oncogene. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares moved up 4.71% in last trading session and was closed at $7.33, while trading in range of $6.90-$7.40. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) year to date performance is 7.48%.
Currently, the leading investigational product (drug and device combination) of Mannkind Corporation (NASDAQ:MNKD), Afrezza is under review by the FDA. At the beginning of the month, Food and Drug Administration (FDA)’s advisory panel recommended approval of Afrezza for use in Diabetes Type 1 and 2. However, FDA later postponed the date of approval for the full review of the drug device to Mid-July. MannKind Corporation (NASDAQ:MNKD) weekly performance is -0.62%. On last trading day company shares ended up $6.41. MannKind Corporation (NASDAQ:MNKD) distance from 50-day simple moving average is 6.88%. Analysts mean target price for the company is $7.57.
Leave a Reply